Keros Therapeutics (NASDAQ:KROS) Issues Earnings Results

Keros Therapeutics (NASDAQ:KROS) issued its quarterly earnings results on Thursday. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $1.66, FiscalAI reports. The company had revenue of $40.01 million during the quarter, compared to analyst estimates of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%.

Keros Therapeutics Trading Down 1.0%

KROS traded down $0.09 during midday trading on Friday, reaching $9.36. The company’s stock had a trading volume of 192,038 shares, compared to its average volume of 297,118. The stock’s 50-day moving average is $11.22 and its 200-day moving average is $11.97. Keros Therapeutics has a 1 year low of $9.26 and a 1 year high of $22.55. The firm has a market capitalization of $185.61 million, a price-to-earnings ratio of -2.53 and a beta of 1.13.

Analysts Set New Price Targets

KROS has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, November 1st. Wells Fargo & Company decreased their price target on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 4th. Zacks Research raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. Leerink Partners cut their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $21.40.

Insider Activity at Keros Therapeutics

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the transaction, the insider owned 27,559 shares in the company, valued at $283,582.11. The trade was a 11.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,343 shares of company stock valued at $54,985 over the last 90 days. Corporate insiders own 12.60% of the company’s stock.

Keros Therapeutics announced that its board has approved a stock repurchase program on Wednesday, September 9th that allows the company to buy back $5 million in outstanding shares. This buyback authorization allows the company to repurchase up to 2.3% of its shares through open market purchases. Share buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-?) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.